Tredje AP fonden Grows Stake in Becton, Dickinson and Company $BDX
Tredje AP fonden increased its stake in Becton, Dickinson and Company (NYSE:BDX) by 28.3% during the third quarter, acquiring an additional 60,000 shares to own a total of 271,720 shares valued at $50.86 million. Other institutional investors like Vanguard Group, Norges Bank, and First Eagle Investment Management also adjusted their holdings in the medical instruments supplier. The article also details recent insider stock sales, analyst ratings, and the company's financial performance, including its latest quarterly earnings, stock buyback authorization, and dividend announcement.
Raiffeisen Bank International AG Has $6.12 Million Stock Position in Becton, Dickinson and Company $BDX
Raiffeisen Bank International AG significantly reduced its stake in Becton, Dickinson and Company (NYSE:BDX) by 57.1% in the third quarter, now holding shares worth $6.12 million. Despite this, other institutional investors have increased their holdings, and the company recently reported strong quarterly earnings, beating analyst expectations. Becton, Dickinson and Company also announced a stock repurchase program and a quarterly dividend of $1.05 per share.
Becton, Dickinson and Company $BDX Shares Sold by Illinois Municipal Retirement Fund
The Illinois Municipal Retirement Fund significantly reduced its stake in Becton, Dickinson and Company (NYSE:BDX) by 74.1% in Q3, selling over 6,000 shares. This comes despite BDX reporting a beat on quarterly earnings expectations and announcing a $10 million share repurchase program and a quarterly dividend of $1.05 per share. Analysts currently hold a consensus "Hold" rating on the stock with a target price of $195.46.
Becton Dickinson stock hits 52-week high at 185.0 USD By Investing.com
Becton Dickinson (BDX) stock has reached a 52-week high of $184.95, reflecting strong investor confidence with a 19.6% year-to-date gain. The company recently reported fiscal first-quarter 2026 results that exceeded expectations, with revenues of $5.25 billion, and has raised its dividend for 55 consecutive years. Despite recent price target adjustments by analysts, BD's performance continues to be robust.
Becton Dickinson stock hits 52-week high at 185.0 USD
Becton Dickinson (BDX) stock has reached a 52-week high of $184.95, reflecting strong investor confidence and a 19.6% year-to-date gain. The medical technology company, valued at $52.4 billion, recently outperformed fiscal Q1 2026 revenue and EPS expectations and announced a $1.6 billion debt repurchase. While analyst price targets have been adjusted, InvestingPro analysis suggests the stock is undervalued, supported by 55 consecutive years of dividend increases.
Former Walgreens Legal Chief Joins Medical Device Giant Becton Dickinson
Lanesha Minnix, previously the general counsel for Walgreens, has been appointed as the new general counsel for Becton Dickinson and Co., a major medical device company. This move follows a series of executive changes in the legal sector, including Michelle Quinn's departure from BD to Medtronic last summer. The article notes that access to the full content requires a subscription to Law.com.
BD and Envetec Pilot Recycling of Polystyrene Petri Dishes into New Lab Products
BD and Envetec Sustainable Technologies have successfully completed a feasibility study demonstrating the recycling of polystyrene Petri dishes into new lab products. Utilizing Envetec's GENERATIONS technology, disinfected lab plastics were converted into reusable manufacturing raw material. This initiative addresses the large volume of single-use plastic consumables in laboratories and aims to establish circular economy solutions for healthcare products, potentially extending to other polymers and consumables.
Fill Finish Manufacturing Market Analysis Report 2026-2035: A $21+ Billion Market by 2030 with Johnson & Johnson, AbbVie, Thermo Fisher Scientific, BD & Co, Baxter, Lonza, and Catalent Leading
The fill finish manufacturing market is projected to grow from $11.96 billion in 2025 to $21.04 billion by 2030, driven by the increasing demand for advanced therapies, personalized medicine, and outsourcing to CMOs. Key trends include the adoption of automated lines, aseptic processing, and single-use consumables. North America currently holds the largest market share, with Asia-Pacific expected to be the fastest-growing region.
Fill Finish Manufacturing Market Analysis Report 2026-2035: A $21+ Billion Market by 2030 with Johnson & Johnson, AbbVie, Thermo Fisher Scientific, BD & Co, Baxter, Lonza, and Catalent Leading
The fill-finish manufacturing market is experiencing significant growth, projected to reach over $21 billion by 2030, driven by increased demand for biopharmaceuticals, cell and gene therapies, and personalized medicine. Key market drivers include advancements in aseptic filling technologies, rising outsourcing to CMOs, and a stronger focus on regulatory compliance. Major players like Johnson & Johnson, AbbVie, and Thermo Fisher Scientific are leading the innovation in this sector, with Asia-Pacific expected to be the fastest-growing region.
Fill Finish Manufacturing Market Analysis Report 2026-2035: A $21+ Billion Market by 2030 with Johnson & Johnson, AbbVie, Thermo Fisher Scientific, BD & Co, Baxter, Lonza, and Catalent Leading
The global fill-finish manufacturing market is projected to grow from $11.96 billion in 2025 to over $21 billion by 2030, driven by surge in demand for cell and gene therapies and biologics. Key industry trends include the adoption of automated fill-finish lines, aseptic processing solutions, and increased outsourcing to contract manufacturing organizations (CMOs).
Berkeley Capital Partners LLC Buys New Position in Becton, Dickinson and Company $BDX
Berkeley Capital Partners LLC recently acquired a new position in Becton, Dickinson and Company (BDX), purchasing 8,507 shares valued at approximately $1.59 million. This makes institutional investors own roughly 86.97% of BDX. Despite insiders selling shares, the company reported strong quarterly earnings, beating expectations, authorized a $10 million stock buyback, and declared a quarterly dividend of $1.05.
Walgreens deal veteran Lanesha Minnix to lead BD legal and public affairs
BD (Becton, Dickinson and Company) has appointed Lanesha Minnix as Executive Vice President and General Counsel, effective March 16, 2026. Minnix, who previously held senior legal roles at Walgreens Boots Alliance where she played a key part in a $24 billion take-private transaction, will lead BD's Law Group and Public Affairs and join the Executive Leadership Team. This appointment comes as BD navigates significant strategic changes, including portfolio adjustments and debt management.
Lanesha Minnix Named General Counsel for BD
BD (Becton, Dickinson and Company) has announced the appointment of Lanesha Minnix as Executive Vice President and General Counsel, effective March 16. Minnix, who previously served as chief legal officer at Walgreens Boots Alliance, will lead BD's Law Group and Public Affairs, reporting to Chairman, CEO, and President Tom Polen. Her appointment is expected to strengthen the company's governance and drive innovation in the healthcare sector.
Assessing West Pharmaceutical Services (WST) Valuation After New US$1b Buyback And Earnings Update
West Pharmaceutical Services (WST) recently announced a new US$1 billion share buyback program and a regular US$0.22 quarterly dividend, following its 2025 earnings report. The stock's current price of around US$248 per share presents a mixed valuation picture, with one narrative suggesting it's 26.7% undervalued (fair value US$338.57) due to growth in GLP-1s and margin expansion, while a DCF model indicates it might be expensive with a fair value of US$103.01. Investors are encouraged to consider these contrasting views and perform their own analysis.
Lanesha Minnix Named General Counsel for BD
BD (Becton, Dickinson and Company) has appointed Lanesha Minnix as its executive vice president and general counsel, effective March 16, 2026. She will lead the Law Group and Public Affairs, reporting to the chairman, CEO, and president, Tom Polen. Minnix previously served as chief legal officer at Walgreens Boots Alliance and held senior roles at Ecolab and Flowserve, bringing extensive experience in legal, corporate affairs, and governance to BD.
Lanesha Minnix Named General Counsel for BD
BD (Becton, Dickinson and Company) has announced the appointment of Lanesha Minnix as executive vice president and general counsel, effective March 16. Minnix, who previously served as EVP and chief legal officer at Walgreens Boots Alliance, will lead BD's Law Group and Public Affairs, reporting to CEO Tom Polen. Her appointment is expected to bolster BD's strategic growth, governance, and operational excellence.
First National Bank of Omaha Acquires New Holdings in Becton, Dickinson and Company $BDX
First National Bank of Omaha has acquired a new stake in Becton, Dickinson and Company (NYSE:BDX), purchasing 12,032 shares valued at approximately $2.25 million. This move is part of broader institutional investment activity, with other hedge funds also adjusting their positions in the medical instruments supplier. The company recently reported strong quarterly earnings, beating analyst estimates, and announced a share repurchase plan, alongside a quarterly dividend.
1 S&P 500 Stock on Our Buy List and 2 We Ignore
StockStory identifies Jack Henry (JKHY) as a top S&P 500 buy due to its strong revenue growth and market-beating return on equity. Conversely, the analysis recommends avoiding Waters Corporation (WAT) and Morgan Stanley (MS) citing shrinking returns on capital and lagging earnings per share respectively.
Becton, Dickinson and Company (NYSE:BDX) Director Sells 953 Shares
Becton, Dickinson and Company (NYSE:BDX) Director Bertram Scott sold 953 shares of the company's stock for a total of $174,027.33, reducing his position by 2.53%. This sale occurred on February 18th, and details were filed with the SEC. After the transaction, Scott directly owns 36,763 shares valued at approximately $6.71 million.
Becton Dickinson & Co. stock outperforms competitors on strong trading day
Becton Dickinson & Co. (BDX) saw its stock rally by 2.99% to $182.68 on Wednesday, outperforming the broader market which also rose. This marks the second consecutive day of gains for the company's shares. The article highlights the stock's performance in comparison to the S&P 500 Index and the Dow Jones Industrial Average.
Drucker Wealth 3.0 LLC Has $943,000 Stake in Becton, Dickinson and Company $BDX
Drucker Wealth 3.0 LLC significantly reduced its stake in Becton, Dickinson and Company (BDX) by 62.9% in Q3, now holding 5,038 shares valued at $943,000, while institutional investors collectively own nearly 87%. BDX reported a quarterly earnings beat and provided 2026 EPS guidance, maintaining a consensus "Hold" rating from analysts with varying price targets. The company also declared a quarterly dividend of $1.05 per share and initiated a $10 million share buyback program.
DNA RNA Banking Services Market Is Going to Boom | Thermo Fisher Scientific • Illumina • 23andMe • AncestryDNA
This report by Coherent Market Insights analyzes the DNA RNA Banking Services Market, predicting substantial growth from 2026 to 2033 due to rising demand and innovation. It covers key market trends, drivers, competitive landscape, and strategic opportunities for industry leaders, identifying major players like Thermo Fisher Scientific and Illumina. The study utilizes analytical tools like SWOT analysis and Porter's Five Forces to provide comprehensive insights and forecasts for various segments and regions.
Baxter Restructuring And Divestiture Plan Tests Turnaround And Valuation Case
Baxter International (NYSE:BAX) is initiating a significant restructuring, including separating its Kidney Care business and implementing a decentralized operating model, following a challenging financial year. Despite a 72.1% stock decline over five years, the company aims to improve profitability and efficiency, with management expecting flat to 1% GAAP sales growth in 2026. Investors face elevated execution risk during this turnaround, but analysts anticipate future earnings and revenue growth, and the stock is considered to be trading at a discount to its fair value.
Fund Update: 1,014,989 BECTON, DICKINSON (BDX) shares added to First Pacific Advisors, LP portfolio
First Pacific Advisors, LP has significantly increased its stake in BECTON, DICKINSON (BDX) by adding 1,014,989 shares, as detailed in a recent SEC 13F filing. This move reflects the fund's holdings as of December 31, 2025. The article also provides a comprehensive overview of recent institutional activity, insider trading, government contracts, and analyst price targets for BDX.
Landmark eye trial: two-thirds on AXPAXLI kept vision at 1 year
Ocular Therapeutix reported positive topline results for its AXPAXLI (OTX-TKI) in the SOL-1 Phase 3 superiority trial for wet AMD. The trial successfully met its FDA-aligned primary endpoint at Week 36, demonstrating that 74.1% of subjects maintained vision, and showed durable Week 52 outcomes with 65.9% maintaining vision, surpassing aflibercept. Despite these strong clinical results, the market reacted negatively, with Ocular Therapeutix (NASDAQ: OCUL) stock declining by 21.28% on the news day.
Integra LifeSciences Announces Key Executive Leadership Appointments
Integra LifeSciences Holdings Corporation has announced key executive leadership appointments, including Teshtar Elavia as corporate vice president and chief technology officer, Michael Hutchinson as executive vice president, chief legal officer and secretary, and Kerri DiPietro as corporate vice president and chief quality officer. The creation of the CTO role emphasizes Integra's commitment to innovation and product development, while the other appointments strengthen the company's legal, compliance, ESG, and global quality functions. These strategic hires aim to drive the company's transformation and long-term value.
Vanguard Group Inc. Increases Stock Position in Becton, Dickinson and Company $BDX
Vanguard Group Inc. has increased its stake in Becton, Dickinson and Company (BDX) by 0.5% in the third quarter, now owning 32,455,790 shares valued at approximately $6.07 billion, representing 11.32% of the company. Despite beating quarterly earnings expectations with $2.91 EPS and $5.25 billion in revenue, Becton, Dickinson and Company provided conservative FY2026 guidance below analyst estimates. The company declared a quarterly dividend of $1.05 and authorized a $10 million share repurchase plan, while analysts maintain a "Hold" rating with an average target price of $195.46.
Heartland Advisors Inc. Purchases 16,805 Shares of Becton, Dickinson and Company $BDX
Heartland Advisors Inc. increased its stake in Becton, Dickinson and Company (NYSE:BDX) by 23.2% in the third quarter, acquiring an additional 16,805 shares. This raised their total holdings to 89,168 shares, valued at $16.69 million, making BDX their 27th largest position. The article also notes recent institutional investor activity, BDX stock performance, dividend declarations, and several analyst rating changes.
Glenview Trust Co Has $11.04 Million Stake in Becton, Dickinson and Company $BDX
Glenview Trust Co recently reduced its holdings in Becton, Dickinson and Company (NYSE:BDX) by 31.8% in Q3, now owning shares worth $11.04 million. Despite this reduction, other institutional investors have increased their stakes. The company also announced a share repurchase program and a quarterly dividend of $1.05 per share.
Integra LifeSciences Announces Key Executive Leadership Appointments
Integra LifeSciences has announced key executive leadership appointments, including Teshtar Elavia as Chief Technology Officer, Michael Hutchinson as Chief Legal Officer, and Kerri DiPietro as Chief Quality Officer. These appointments aim to strengthen the company's innovation engine, legal and compliance functions, and global quality management system, reflecting a commitment to strategic growth and transformation.
5 Must-Read Analyst Questions From BD's Q4 Earnings Call
BD (Becton, Dickinson and Company) reported strong Q4 results with revenue and EPS exceeding analyst estimates, driven by growth in biologic drug delivery, advanced tissue regeneration, and pharmacy automation. Despite challenges from China and vaccine-related pressures, the company maintained focus on investments in growth platforms and productivity. Analyst questions highlighted concerns about future guidance, portfolio changes, and the long-term outlook for GLP-1 devices, with management providing clarifying responses.
M&G PLC Increases Stock Position in Becton, Dickinson and Company $BDX
M&G PLC increased its stake in Becton, Dickinson and Company ($BDX) by 4.9% in Q3, now owning 935,480 shares valued at approximately $174.9 million. The medical instruments supplier exceeded Q4 earnings expectations with $2.91 EPS and $5.25 billion in revenue, and announced a $10 million share buyback program and a $1.05 quarterly dividend. Despite mixed analyst sentiment with a consensus Hold rating and a $195.46 price target, several other institutional investors also increased their holdings in the company.
Becton, Dickinson and Company’s Bilal Muhsin on the future of Connected Care
Bilal Muhsin of Becton, Dickinson and Company (BD) discusses the company's strategic shift to focus on Connected Care, emphasizing the integration of medication management, automated dispensing, and patient monitoring. He highlights BD's priorities, including advancing infusion management, pharmacy automation, and patient monitoring, all integrated into a unified ecosystem. Muhsin also elaborates on BD's approach to AI, data governance, and anticipated growth in healthcare, focusing on system-level integration and delivering measurable improvements in patient safety and operational efficiency.
Bright Horizons Family Solutions Inc. (NYSE:BFAM) Q4 2025 Earnings Call Transcript
Bright Horizons Family Solutions Inc. (NYSE:BFAM) reported a strong Q4 and full-year 2025, with revenue up 9% to $734 million in Q4 and adjusted EPS increasing 17% to $1.15, exceeding expectations. The company saw robust growth in back-up care and ed advisory segments, alongside steady performance in full-service, despite portfolio rationalization efforts. For 2026, Bright Horizons projects revenue between $3.075 billion and $3.125 billion and adjusted EPS in the range of $4.90 to $5.10, driven by continued demand and strategic initiatives.
Cibc World Market Inc. Has $8.25 Million Stake in Becton, Dickinson and Company $BDX
Cibc World Market Inc. significantly increased its stake in Becton, Dickinson and Company (NYSE:BDX) by 89.7% in Q3, now holding 44,098 shares valued at $8.25 million. The medical instruments supplier exceeded Q4 earnings expectations with EPS of $2.91 and revenue of $5.25 billion, and announced a quarterly dividend of $1.05. Despite institutional ownership of nearly 87%, analyst sentiment remains mixed, with an average "Hold" rating and a target price of $195.46.
IRADIMED Dividend Hike Follows Record Revenue And New MRI Pump Rollout
IRADIMED (NasdaqGM:IRMD) announced an increased quarterly dividend to US$0.20 per share, following 18 consecutive quarters of record revenue and strong double-digit growth in sales and earnings. The company is experiencing robust adoption of its existing MRI-compatible devices and is shipping its new 3870 infusion pump, with management confident in future product launches and domestic replacement demand. While the dividend hike signals strong financial health, investors are advised to monitor the rollout and potential competitive pressures, especially given recent insider selling.
Citi Raises Becton Dickinson (BDX) PT to $198 after Life Sciences Sale Update
Citi analyst Joanne Wuensch increased her price target for Becton, Dickinson and Company (NYSE:BDX) to $198 from $185.70, maintaining a Buy rating after updating her financial model to reflect the sale of the Life Sciences business. BDX's Q1 2026 earnings exceeded expectations, with revenue reaching $5.3 billion and adjusted EPS at $2.91, driven by strong commercial momentum and growth in key platforms. The company plans to distribute $4 billion from the sale, with $2 billion allocated to share repurchases and $2 billion to debt reduction, aligning with a more focused capital allocation strategy.
Citi Raises Becton Dickinson (BDX) PT to $198 after Life Sciences Sale Update
Citi analyst Joanne Wuensch increased her price target for Becton, Dickinson and Company (NYSE: BDX) to $198 from $185.70, maintaining a Buy rating. This adjustment follows an update to Citi's financial model to reflect the sale of BDX's Life Sciences business. BDX's fiscal Q1 2026 earnings exceeded expectations with $5.3 billion in revenue, and the company plans a $4 billion cash distribution from the Life Sciences sale, allocating $2 billion to share repurchases and $2 billion to debt reduction.
Becton, Dickinson and Company (NYSE:BDX) Downgraded by Zacks Research to Strong Sell
Zacks Research has downgraded Becton, Dickinson and Company (NYSE:BDX) from a "hold" to a "strong sell" rating. This downgrade, combined with pessimistic notes from major banks like JPMorgan, Wells Fargo, and Citigroup, has contributed to near-term selling pressure on the stock. Despite reporting a Q4 beat, providing positive FY 2026 guidance, completing a significant spin-off, and authorizing a stock buyback, sell-side coverage remains mixed for BDX.
Krilogy Financial LLC Takes Position in Becton, Dickinson and Company $BDX
Krilogy Financial LLC has initiated a new position in Becton, Dickinson and Company (BDX) by purchasing 8,332 shares valued at approximately $1.47 million during the third quarter. Institutional investors now collectively own nearly 87% of the company's stock. This move comes as BDX recently beat Q4 earnings expectations, provided FY2026 guidance, authorized a $10 million share buyback, and completed a spin-off of its Biosciences & Diagnostics business to become a pure-play MedTech company, a shift that has garnered mixed analyst reactions.
Becton Dickinson outlines $12.35–$12.65 EPS guidance for 2026 with $4B cash deployment following Waters transaction
Becton Dickinson (BDX) has provided its 2026 adjusted EPS guidance, anticipating it will fall between $12.35 and $12.65. This outlook includes a plan to deploy $4 billion in cash by the end of 2024, half of which will be used for share repurchases and the other half for debt reduction, following the Waters transaction. The company expects organic revenue growth of 5.75% to 6.25% in 2026 (excluding recent acquisitions).
Citi Raises Becton Dickinson (BDX) PT to $198 after Life Sciences Sale Update
Citi analyst Joanne Wuensch increased her price target for Becton, Dickinson and Company (NYSE: BDX) to $198 from $185.70, maintaining a Buy rating after the firm updated its financial model for the sale of the Life Sciences business. BDX's Q1 2026 results exceeded expectations, with revenue reaching $5.3 billion and adjusted EPS at $2.91. The company plans to close the Life Sciences unit sale, generating $4 billion for share repurchases and debt reduction, aligning with its "Excellence Unleashed" agenda.
West Pharmaceutical Services Margins Slip To 16.3% Raising Questions Around Bullish Growth Narratives
West Pharmaceutical Services (WST) reported its FY 2025 third-quarter results, showing a slip in net profit margins from 17.4% to 16.3% and 6% revenue growth, which trails the broader US market. Despite analyst consensus forecasting margin improvement and future revenue potential driven by GLP-1 and high-value product components, the company's P/E ratio of 35.6x is significantly higher than peers and its DCF fair value, raising concerns for cautious investors. The article highlights a tension between bullish growth narratives and current financial performance, noting that current figures challenge some market expectations.
embecta names new Chairman of the Board and Lead Independent Director
Embecta Corp. (Nasdaq: EMBC) has announced new leadership appointments to its Board of Directors. Devdatt "Dev" Kurdikar has been elected as Chairman of the Board, and Dr. Claire Pomeroy has been appointed as Lead Independent Director, effective immediately. These changes follow the retirement of LTG (Ret.) David F. Melcher, the previous Non-Executive Chairman.
Assessing Becton Dickinson (BDX) Valuation After Recent Share Price Weakness
Becton Dickinson (BDX) has experienced a nearly 9% year-to-date decline in share price, now trading at $177.81 with an intrinsic value gap of about 21% and a 10% discount to analyst targets. Despite recent weakness, the company is seen as undervalued with a fair value estimate around $205, supported by the upcoming separation of its Biosciences and Diagnostic Solutions business, its focus on medical technology, and anticipated share buybacks. However, risks include tariff pressures and execution challenges related to the business separation.
Globus Medical (GMED) to Report Q4 Results: Wall Street Expects Earnings Growth
Globus Medical (GMED) is projected to report a significant year-over-year increase in Q4 2025 earnings and revenues, with earnings expected to rise by 26.2% to $1.06 per share and revenues by 19.9% to $787.85 million. The company's positive Earnings ESP of +3.92% combined with a Zacks Rank #2 suggests a high likelihood of an earnings beat, building on a history of outperforming consensus EPS estimates in three of the last four quarters. Another industry player, Glaukos (GKOS), is also expected to beat estimates with an Earnings ESP of +11.94% and a Zacks Rank #3.
TD Cowen Raises Becton, Dickinson and Company (NYSE:BDX) Price Target to $189.00
TD Cowen has increased its price target for Becton, Dickinson and Company (NYSE:BDX) to $189 from $183, while reiterating a "hold" rating. This adjustment follows Becton, Dickinson beating its Q1 earnings and revenue estimates, reporting $2.91 EPS against an expected $2.81, and revenues of $5.25 billion. The company also announced a modest share buyback of $10 million and tender offers to repurchase up to $1.6 billion in debt, reflecting active capital management.
A Look At QuidelOrtho (QDEL) Valuation After Earnings Update And CFO Transition News
QuidelOrtho (QDEL) recently released its Q4 and full-year 2025 results and provided 2026 revenue guidance, alongside news of a CFO transition. Despite a significant decline in its 1-year share price, the company's valuation narrative suggests it is 24.9% undervalued, with a fair value target of $38.33 per share. This positive outlook is partly driven by the acquisition of LEX Diagnostics and its potential to boost recurring revenues with rapid molecular point-of-care platforms, though ongoing challenges like COVID testing decline and China pricing pressures are noted risks.
Becton, Dickinson and Company (NYSE:BDX) Given Average Recommendation of "Hold" by Brokerages
Becton, Dickinson and Company (NYSE:BDX) has received a "Hold" consensus recommendation from fourteen brokerages, with nine analysts rating it a "hold" and five a "buy." The average one-year price target is $196.00, though targets vary significantly. The company recently completed a spin-off, reported strong Q1 results, and initiated debt tender offers and a share buyback program.
Candriam S.C.A. Has $2.87 Million Position in Becton, Dickinson and Company $BDX
Candriam S.C.A. decreased its stake in Becton, Dickinson and Company (BDX) by 33.7% in Q3, now holding 15,305 shares worth approximately $2.865 million. BDX recently completed a spin-off of its biosciences & diagnostics unit, becoming a pure-play medical technology company and reporting strong Q1 FY2026 sales and EPS. Despite mixed analyst sentiment, with an average "Hold" rating and $196 price target, the company declared a quarterly dividend of $1.05 and authorized a $10 million share repurchase plan.
